Today, hepatitis C treatment is largely based on oral DAA tablet regimens. The goal is to achieve SVR (virus remains undetectable after therapy), which is considered cure. Treatment duration is typically measured in weeks, but cirrhosis, prior treatment failure, and special clinical situations can affect regimen choice and length. Before starting, clinicians assess liver disease stage, viral load, comorbidities, and potential drug interactions. Proper selection and structured monitoring are key drivers of success.